{"component": "contracts", "props": {"contracts": [{"intro": "This Assignment Agreement, dated as of the 2 day of July, 2006 , (the \u201cEffective Date\u201d), is entered into by and between BioLineRx Ltd. (\u201cBioLine\u201d), BioLine Innovations Jerusalem, LP (\u201cBIJ\u201d), Bar-Ilan Research and Development Company Ltd. (\u201cBIRAD\u201d) and Ramot at Tel Aviv University Ltd. (\u201cRamot\u201d, and together with BIRAD, the \u201cLicensors\u201d).", "id": "cPvNKeemuFF", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-12.htm", "category_name": "Assignment Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/cPvNKeemuFF", "title": "CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. ASSIGNMENT AGREEMENT", "group_id": "a5YSjjpNeNB", "group_samples": [{"label": "Assignment Agreement (BioLineRx Ltd.)", "uri": "/contracts/cPvNKeemuFF", "published": true}, {"label": "Assignment Agreement (BioLineRx Ltd.)", "uri": "/contracts/a5YSjjpNeNB", "published": true}], "group_size": 2, "tags": [{"name": "Assignment Agreement", "type": "category", "uri": "/contracts/tagged/assignment-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Bridge Loan Agreement (this \"Agreement\") is entered into as of January 10, 2007 (the \"Effective Date\"), by and between BioLineRx Ltd., an Israeli company (the \"Company\"), and Pan Atlantic Investments Limited, a Barbados company (the \"Lender\").", "id": "f3LVO23SEVj", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-14.htm", "category_name": "Bridge Loan Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/f3LVO23SEVj", "title": "Bridge Loan Agreement", "group_id": "aweOLIlDacZ", "group_samples": [{"label": "Bridge Loan Agreement (BioLineRx Ltd.)", "uri": "/contracts/f3LVO23SEVj", "published": true}, {"label": "Bridge Loan Agreement (BioLineRx Ltd.)", "uri": "/contracts/aweOLIlDacZ", "published": true}], "group_size": 2, "tags": [{"name": "Bridge Loan Agreement", "type": "category", "uri": "/contracts/tagged/bridge-loan-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Further to our discussions, this is to set forth in writing our agreements regarding your engagement as the General Manager of a wholly owned subsidiary company which may be established by us as the management company of a biotechnology incubator in Jerusalem which shall be established by us if and when we shall win a tender of the Office of the Israeli Chief Scientist to establish, operate and manage such an incubator. For purposes of this letter agreement, we shall be referred to as \"BioLine\", the biotechnology incubator shall be referred to as the \"Incubator\", and the Incubator's management company shall be referred to as the \"Management Company\".", "id": "bKxLccf0V9R", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-3.htm", "category_name": "Engagement Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/bKxLccf0V9R", "title": "October 13, 2004", "group_id": "bKxLccf0V9R", "group_samples": [{"label": "Engagement Agreement (BioLineRx Ltd.)", "uri": "/contracts/bKxLccf0V9R", "published": true}, {"label": "Engagement Agreement (BioLineRx Ltd.)", "uri": "/contracts/gNnFFrQAlSe", "published": true}], "group_size": 2, "tags": [{"name": "Engagement Agreement", "type": "category", "uri": "/contracts/tagged/engagement-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This VOTING AND STANDSTILL AGREEMENT (this \u201cAgreement\u201d), dated as of July 26, 2017, is entered into between BioLineRx Ltd. (\u201cBioLineRx\u201d or the \u201cCompany\u201d) and Biotechnology Value Fund, together with any affiliates, control persons, nominees or others under common control (\u201cBVF\u201d).", "id": "e4y4UAoYVrO", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891317002187/exhibit_10-4.htm", "category_name": "Voting and Standstill Agreement", "company_name": "BioLineRx Ltd.", "created": "July 31st, 2017", "published": true, "pretty": null, "uri": "/contracts/e4y4UAoYVrO", "title": "VOTING AND STANDSTILL AGREEMENT", "group_id": "bQDzJHSt7PL", "group_samples": [{"label": "Voting and Standstill Agreement (Biotechnology Value Fund L P)", "uri": "/contracts/bQDzJHSt7PL", "published": true}, {"label": "Voting and Standstill Agreement (BioLineRx Ltd.)", "uri": "/contracts/e4y4UAoYVrO", "published": true}], "group_size": 2, "tags": [{"name": "Voting and Standstill Agreement", "type": "category", "uri": "/contracts/tagged/voting-and-standstill-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS LICENSE AGREEMENT (the \u201cAgreement\u201d) is entered into as of this 25 day of November, 2007 (the \u201cEffective Date\u201d), by and among BioLine Innovations Jerusalem, LP, a limited partnership formed and existing under the laws of the State of Israel, having a place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem, 91450, Israel (\u201cBioLine\u201d), and Innovative Pharmaceutical Concepts (IPC) Inc., a company formed and existing under the laws of the British Virgin Islands, having a place of business at Geneva Place, 2nd Floor, 333 Waterfront Drive, P.O. Box 3339, Road Town, Tortola, British Virgin Islands (\u201cLicensor\u201d).", "id": "bk9UmFrDykU", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-16.htm", "category_name": "License Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/bk9UmFrDykU", "title": "LICENSE AGREEMENT", "group_id": "bk9UmFrDykU", "group_samples": [{"label": "License Agreement (BioLineRx Ltd.)", "uri": "/contracts/bk9UmFrDykU", "published": true}, {"label": "License Agreement (BioLineRx Ltd.)", "uri": "/contracts/iVic2YLhiz", "published": true}], "group_size": 2, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This License Agreement is entered into as of this 15 day of April, 2004 (the \u201cEffective Date\u201d), by and among BioLineRx Ltd., a company formed under the laws of Israel, having a place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem, 91450, Israel (\u201cBioLine\u201d); Bar-Ilan Research and Development Company Ltd., a company formed under the laws of Israel, having a place of business at Bar-Ilan University, Ramat Gan, 52900 (\u201cBIRAD\u201d); and Ramot at Tel Aviv University Ltd., a company formed under the laws of Israel, having a place of business at Tel Aviv University in Ramat-Aviv, Tel Aviv 61392, Israel (\u201cRamot\u201d). BIRAD and Ramot shall be referred to together as the \u201cLicensors\u201d.", "id": "jl3S8WeJybR", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-8.htm", "category_name": "Research and License Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/jl3S8WeJybR", "title": "RESEARCH AND LICENSE AGREEMENT", "group_id": "dx0b6qaMDBL", "group_samples": [{"label": "Research and License Agreement (BioLineRx Ltd.)", "uri": "/contracts/jl3S8WeJybR", "published": true}, {"label": "Research and License Agreement (BioLineRx Ltd.)", "uri": "/contracts/dx0b6qaMDBL", "published": true}], "group_size": 2, "tags": [{"name": "Research and License Agreement", "type": "category", "uri": "/contracts/tagged/research-and-license-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This License Agreement (the \u201cAgreement\u201d) is entered into on June 20, 2010 (the \u201cExecution Date\u201d) between Cypress Bioscience, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 4350 Executive Drive, Suite 325, San Diego, CA 92121 (\u201cCypress\u201d), and BioLineRx Ltd., a corporation organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (collectively, \u201cBioLineRx\u201d). BioLineRx and Cypress are sometimes referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "130R4qVyoLg", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-24.htm", "category_name": "License Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/130R4qVyoLg", "title": "LICENSE AGREEMENT", "group_id": "130R4qVyoLg", "group_samples": [{"label": "License Agreement (BioLineRx Ltd.)", "uri": "/contracts/130R4qVyoLg", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS ASSIGNMENT (the \"Assignment\") is made effective as of January 1, 2009, by and between BioLine Innovations Jerusalem, Limited Partnership (\"Assignor\") and BioLineRx, Ltd. (\"Assignee\").", "id": "1AIZkamxMAG", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-7.htm", "category_name": "Assignment of License Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/1AIZkamxMAG", "title": "ASSIGNMENT OF BL-1040 PROJECT", "group_id": "1AIZkamxMAG", "group_samples": [{"label": "Assignment of License Agreement (BioLineRx Ltd.)", "uri": "/contracts/1AIZkamxMAG", "published": true}], "group_size": 1, "tags": [{"name": "Assignment of License Agreement", "type": "category", "uri": "/contracts/tagged/assignment-of-license-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "[*] Represents material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.", "id": "1BezyCmp4v0", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891319000965/exhibit_4-47.htm", "category_name": "Patent & Know-How License Agreement", "company_name": "BioLineRx Ltd.", "created": "March 28th, 2019", "published": true, "pretty": null, "uri": "/contracts/1BezyCmp4v0", "title": "Contract", "group_id": "1BezyCmp4v0", "group_samples": [{"label": "Patent & Know How License Agreement (BioLineRx Ltd.)", "uri": "/contracts/1BezyCmp4v0", "published": true}], "group_size": 1, "tags": [{"name": "Patent & Know-How License Agreement", "type": "category", "uri": "/contracts/tagged/patent-know-how-license-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "England", "type": "jurisdiction", "uri": "/contracts/tagged/england-gb"}]}, {"intro": "THIS AMENDMENT AGREEMENT, dated as of the 7th day of March, 2006, (the \"Effective Date\"), is entered into by and between BioLineRx Ltd. (\"BioLine\"), Bar-Ilan Research and Development Company Ltd. (\"BIRAD\") and Ramot at Tel Aviv University Ltd. (\"Ramot\", and together with BIRAD, the \"Licensors\").", "id": "1USjffB1ZO6", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-11.htm", "category_name": "Research and License Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/1USjffB1ZO6", "title": "AMENDMENT AGREEMENT", "group_id": "1USjffB1ZO6", "group_samples": [{"label": "Research and License Agreement (BioLineRx Ltd.)", "uri": "/contracts/1USjffB1ZO6", "published": true}], "group_size": 1, "tags": [{"name": "Research and License Agreement", "type": "category", "uri": "/contracts/tagged/research-and-license-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "that certain AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF UP TO US$ 40,000,000 dated as of September 14, 2022 (the \u201cLoan Agreement\u201d) between KREOS CAPITAL VII AGGREGATOR SCSP, a special limited partnership incorporated in Luxembourg under registered number B264706 whose registered office is at 1 Boulevard de la Foire, L-1528, Luxembourg (the \u201cLender\u201d or \u201cKreos\u201d, which expressions shall include its successors and assigns), and BIOLINERX LTD., a company incorporated in Israel under registered number 513398750 whose registered office is at 2 HaMa\u2019ayan Street, Modi\u2019in 7177871, Israel (the \u201cBorrower\u201d).", "id": "1e0wQJn3Vmf", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-2.htm", "category_name": "Loan Agreement", "company_name": "BioLineRx Ltd.", "created": "November 21st, 2024", "published": true, "pretty": null, "uri": "/contracts/1e0wQJn3Vmf", "title": "FIRST AMENDMENT (this \u201cAmendment\u201d)", "group_id": "1e0wQJn3Vmf", "group_samples": [{"label": "Loan Agreement (BioLineRx Ltd.)", "uri": "/contracts/1e0wQJn3Vmf", "published": true}], "group_size": 1, "tags": [{"name": "Loan Agreement", "type": "category", "uri": "/contracts/tagged/loan-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Employment Agreement (this \u201cAgreement\u201d) is entered into on this 8th day of August, 2011 by and between BioLineRx Ltd., a company organized under the laws of the State of Israel, with its offices at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (\u201cBioLine\u201d), and David Malek, I.D. Number 034371252 with an address at 19 Stephan Weis, Haifa (the \u201cExecutive\u201d).", "id": "2KArfcDSBLU", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891312000579/exhibit_4-30.htm", "category_name": "Employment Agreement", "company_name": "BioLineRx Ltd.", "created": "February 29th, 2012", "published": true, "pretty": null, "uri": "/contracts/2KArfcDSBLU", "title": "Employment Agreement", "group_id": "2KArfcDSBLU", "group_samples": [{"label": "Employment Agreement (BioLineRx Ltd.)", "uri": "/contracts/2KArfcDSBLU", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Consulting Agreement (the \u201cAgreement\u201d) is entered into as of January 1, 2014 (the \u201cEffective Date\u201d) by and between BioLineRx Ltd., a company organized under the laws of the State of Israel, with its offices at 19 Hartum Street, P.O. Box 45158, Jerusalem 9777518 (\u201cBioLine\u201d), and Arnon Aharon, M.D., I.D. number 023699796, with an address at 12 Yavne Street, Tel-Aviv 6579111 (\u201cConsultant\u201d).", "id": "2LJyBpUnlZ9", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891314000942/exhibit_4-34.htm", "category_name": "Consulting Agreement", "company_name": "BioLineRx Ltd.", "created": "March 17th, 2014", "published": true, "pretty": null, "uri": "/contracts/2LJyBpUnlZ9", "title": "Consulting Agreement", "group_id": "2LJyBpUnlZ9", "group_samples": [{"label": "Consulting Agreement (BioLineRx Ltd.)", "uri": "/contracts/2LJyBpUnlZ9", "published": true}], "group_size": 1, "tags": [{"name": "Consulting Agreement", "type": "category", "uri": "/contracts/tagged/consulting-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "The undersigned hereby agree that the Schedule 13G with respect to the Ordinary Shares, par value NIS 0.01 per share of BioLineRx Ltd. (the \u201cSchedule 13G\u201d) is, and any amendments thereto executed by each of us shall be, filed on behalf of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein.", "id": "2dCY2IobLUk", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000101905612000122/ex_2.htm", "category_name": "Joint Filing Agreement", "company_name": "BioLineRx Ltd.", "created": "February 7th, 2012", "published": true, "pretty": null, "uri": "/contracts/2dCY2IobLUk", "title": "JOINT FILING AGREEMENT AMONG PAN ATLANTIC BANK AND TRUST LIMITED, FCMI FINANCIAL CORPORATION AND ALBERT D. FRIEDBERG", "group_id": "2dCY2IobLUk", "group_samples": [{"label": "Joint Filing Agreement (BioLineRx Ltd.)", "uri": "/contracts/2dCY2IobLUk", "published": true}], "group_size": 1, "tags": [{"name": "Joint Filing Agreement", "type": "category", "uri": "/contracts/tagged/joint-filing-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This letter shall serve as an amendment (the \"Amendment\") to that certain Employment Agreement, dated May 24, 2009, by and between BiolineRx Ltd. (\"Bioline\") and Philip Serlin (the \"Employee\"), as amended, (the \"Employment Agreement\"). Defined terms used herein and not otherwise defined herein shall have the meaning ascribed to them in the Employment Agreement.", "id": "37aM3T1Spva", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/exhibit_4-2.htm", "category_name": "Employment Agreement", "company_name": "BioLineRx Ltd.", "created": "February 23rd, 2021", "published": true, "pretty": null, "uri": "/contracts/37aM3T1Spva", "title": "Re: Amendment to Employment Agreement", "group_id": "37aM3T1Spva", "group_samples": [{"label": "Employment Agreement (BioLineRx Ltd.)", "uri": "/contracts/37aM3T1Spva", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Ordinary Shares and American Depositary Shares of BioLineRx Ltd. and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.", "id": "3VBnkUtetFu", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000101905612000254/ex99_5.htm", "category_name": "Joint Filing Agreement", "company_name": "BioLineRx Ltd.", "created": "February 27th, 2012", "published": true, "pretty": null, "uri": "/contracts/3VBnkUtetFu", "title": "JOINT FILING AGREEMENT", "group_id": "3VBnkUtetFu", "group_samples": [{"label": "Joint Filing Agreement (BioLineRx Ltd.)", "uri": "/contracts/3VBnkUtetFu", "published": true}], "group_size": 1, "tags": [{"name": "Joint Filing Agreement", "type": "category", "uri": "/contracts/tagged/joint-filing-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Stock Purchase Agreement (the \u201cAgreement\u201d) is entered into as of October 2, 2018 (the \u201cEffective Date\u201d) by and between BioLineRx Ltd., an Israeli company having a place of business at 2 HaMa\u2019ayan Street, Modi\u2019in 7177871 (\u201cBioLine\u201d), and Biokine Therapeutics Ltd., an Israeli company having a place of business at Weizmann Science Park, P.O. Box 2213, Rehovot, 76120 (\u201cBiokine\u201d). Biokine and BioLine are sometimes referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "3px90UiBNzj", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891318002615/exhibit_10-2.htm", "category_name": "Stock Purchase Agreement", "company_name": "BioLineRx Ltd.", "created": "October 3rd, 2018", "published": true, "pretty": null, "uri": "/contracts/3px90UiBNzj", "title": "STOCK PURCHASE AGREEMENT", "group_id": "3px90UiBNzj", "group_samples": [{"label": "Stock Purchase Agreement (BioLineRx Ltd.)", "uri": "/contracts/3px90UiBNzj", "published": true}], "group_size": 1, "tags": [{"name": "Stock Purchase Agreement", "type": "category", "uri": "/contracts/tagged/stock-purchase-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "KREOS CAPITAL V (EXPERT FUND) L.P. a company incorporated in Jersey whose registered office is at 47 Esplanade, St Helier, Jersey (the \u201cLender\u201d, which expression shall include its successors and assigns);", "id": "4SVSVtGuy8U", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891318002615/exhibit_10-3.htm", "category_name": "Loan Agreement", "company_name": "BioLineRx Ltd.", "created": "October 3rd, 2018", "published": true, "pretty": null, "uri": "/contracts/4SVSVtGuy8U", "title": "AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF UP TO US$ 10,000,000 Dated October 2, 2018 Between", "group_id": "4SVSVtGuy8U", "group_samples": [{"label": "Loan Agreement (BioLineRx Ltd.)", "uri": "/contracts/4SVSVtGuy8U", "published": true}], "group_size": 1, "tags": [{"name": "Loan Agreement", "type": "category", "uri": "/contracts/tagged/loan-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS UNDERWRITER WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES (this \u201cWarrant\u201d) certifies that, for value received, _____________ or its assigns (the \u201cHolder\u201d) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after January 22, 2021 (the \u201cInitial Exercise Date\u201d) and on or prior to 5:00 p.m. (New York City time) on January 19, 2026 (the \u201cTermination Date\u201d) but not thereafter, to subscribe for and purchase from BIOLINERX LTD., a company organized under the laws of the State of Israel (the \u201cCompany\u201d), up to [\u0178] Ordinary Shares, par value NIS 0.10 per share, of the Company (the \u201cWarrant Shares\u201d) represented by [\u0178] American Depositary Shares (each, an \u201cADS\u201d and, collectively, the \u201cADSs\u201d and the ADSs issuable upon exercise of this Warrant, the \u201cWarrant ADSs\u201d), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant ", "id": "4b8jH9Autou", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891321000214/exhibit_10-1.htm", "category_name": "Underwriter Warrant Agreement", "company_name": "BioLineRx Ltd.", "created": "January 21st, 2021", "published": true, "pretty": null, "uri": "/contracts/4b8jH9Autou", "title": "UNDERWRITER WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD.", "group_id": "4b8jH9Autou", "group_samples": [{"label": "Underwriter Warrant Agreement (BioLineRx Ltd.)", "uri": "/contracts/4b8jH9Autou", "published": true}], "group_size": 1, "tags": [{"name": "Underwriter Warrant Agreement", "type": "category", "uri": "/contracts/tagged/underwriter-warrant-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES (this \"Warrant\") certifies that, for value received, _____________ or its assigns (the \"Holder\") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the \"Initial Exercise Date\") and on or prior to 5:00 p.m. (New York City time) on August [*], 20311 (the \"Termination Date\") but not thereafter, to subscribe for and purchase from BIOLINERX LTD., a company organized under the laws of the State of Israel (the \"Company\"), up to _______ Ordinary Shares, par value NIS 0.10 per share, of the Company (the \"Warrant Shares\"), represented by American Depositary Shares (each, an \"ADS\" and, collectively, the \"ADSs\" and the ADSs issuable upon exercise of this Warrant, the \"Warrant ADSs\"), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b).", "id": "4tiZLYzSPbY", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891326004334/exhibit_10-3.htm", "category_name": "Warrant Agreement", "company_name": "BioLineRx Ltd.", "created": "August 31st, 2026", "published": true, "pretty": null, "uri": "/contracts/4tiZLYzSPbY", "title": "WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES BIOLINERX LTD.", "group_id": "4tiZLYzSPbY", "group_samples": [{"label": "Warrant Agreement (BioLineRx Ltd.)", "uri": "/contracts/4tiZLYzSPbY", "published": true}], "group_size": 1, "tags": [{"name": "Warrant Agreement", "type": "category", "uri": "/contracts/tagged/warrant-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS AMENDMENT AGREEMENT, dated as of the 20th day of December, 2005, (the \u201cEffective Date\u201d), is entered into by and between BioLineRx Ltd. (\u201cBioLine\u201d), Bar-Ilan Research and Development Company Ltd. (\u201cBIRAD\u201d) and Ramot at Tel Aviv University Ltd. (\u201cRamot\u201d, and together with BIRAD, the \u201cLicensors\u201d).", "id": "51VrQokL2EB", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-10.htm", "category_name": "Amendment Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/51VrQokL2EB", "title": "AMENDMENT AGREEMENT", "group_id": "51VrQokL2EB", "group_samples": [{"label": "Amendment Agreement (BioLineRx Ltd.)", "uri": "/contracts/51VrQokL2EB", "published": true}], "group_size": 1, "tags": [{"name": "Amendment Agreement", "type": "category", "uri": "/contracts/tagged/amendment-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. [*] indicates that information has been redacted.", "id": "5FH7NFTIlvy", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/exhibit_4-22.htm", "category_name": "Patent & Know-How License Agreement", "company_name": "BioLineRx Ltd.", "created": "March 16th, 2022", "published": true, "pretty": null, "uri": "/contracts/5FH7NFTIlvy", "title": "Contract", "group_id": "5FH7NFTIlvy", "group_samples": [{"label": "Patent & Know How License Agreement (BioLineRx Ltd.)", "uri": "/contracts/5FH7NFTIlvy", "published": true}], "group_size": 1, "tags": [{"name": "Patent & Know-How License Agreement", "type": "category", "uri": "/contracts/tagged/patent-know-how-license-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "England", "type": "jurisdiction", "uri": "/contracts/tagged/england-gb"}]}, {"intro": "This Investment and Collaboration Agreement (the \u201cAgreement\u201d) is entered into as of December 16, 2014 (the \u201cEffective Date\u201d) by and between Novartis Pharma AG, a corporation organized and existing under the laws of Switzerland and having its principal place of business at Lichtstrasse 35, CH-4056, Basel, Switzerland (\u201cNVS\u201d), and BioLineRx Ltd., a company organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, Jerusalem, 91450, Israel (\u201cBioLine\u201d).", "id": "5W7AmwJsqXI", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891315000973/exhibit_4-38.htm", "category_name": "Investment and Collaboration Agreement", "company_name": "BioLineRx Ltd.", "created": "March 23rd, 2015", "published": true, "pretty": null, "uri": "/contracts/5W7AmwJsqXI", "title": "Investment and Collaboration Agreement by and between BioLineRx Ltd. and Novartis Pharma AG December 16, 2014", "group_id": "5W7AmwJsqXI", "group_samples": [{"label": "Investment and Collaboration Agreement (BioLineRx Ltd.)", "uri": "/contracts/5W7AmwJsqXI", "published": true}], "group_size": 1, "tags": [{"name": "Investment and Collaboration Agreement", "type": "category", "uri": "/contracts/tagged/investment-and-collaboration-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel, Fax: +972-2-658 6689; email: Shoshi.Keynan@yissum.co.il, Attention: Shoshi Keynan ( \u201cYissum\u201d) of the one part; and", "id": "5ktexajtqam", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-29.htm", "category_name": "License Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/5ktexajtqam", "title": "EN-101/BL-7040 LICENSE AGREEMENT June 23, 2011", "group_id": "5ktexajtqam", "group_samples": [{"label": "License Agreement (BioLineRx Ltd.)", "uri": "/contracts/5ktexajtqam", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This License Agreement (this \u201cAgreement\u201d) is entered into as of November 20, 2024 (the \u201cLicense Effective Date\u201d), by and between BioLineRx Ltd., a company organized under the laws of the State of Israel, having a place of business at Modi\u2019in Technology Park, 2 HaMa\u2019ayan Street, Modi\u2019in, 7177871, Israel, together with its Affiliates, (\u201cBioLine\u201d) and Ayrmid Pharma Ltd., a company organized under the laws of Ireland, having a place of business at C/o Byrne Wallace, 88 Harcourt Street, Dublin 2, Ireland, together with its Affiliates, (\u201cAyrmid\u201d). Each of BioLine and Ayrmid may be referred to herein as a \u201cParty\u201d and together as the \u201cParties.\u201d", "id": "5qm1G7DT6YY", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-1.htm", "category_name": "License Agreement", "company_name": "BioLineRx Ltd.", "created": "November 21st, 2024", "published": true, "pretty": null, "uri": "/contracts/5qm1G7DT6YY", "title": "been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed License Agreement", "group_id": "5qm1G7DT6YY", "group_samples": [{"label": "License Agreement (BioLineRx Ltd.)", "uri": "/contracts/5qm1G7DT6YY", "published": true}], "group_size": 1, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This letter shall serve as an amendment (the \"Amendment\") to that certain Employment Agreement, dated April 2, 2014, by and between BiolineRx Ltd. (\"Bioline\") and Abi Vainstein (the \"Employee\"), as amended, (the \"Employment Agreement\"). Defined terms used herein and not otherwise defined herein shall have the meaning ascribed to them in the Employment Agreement.", "id": "628QitEAA73", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891321000741/exhibit_4-6.htm", "category_name": "Employment Agreement", "company_name": "BioLineRx Ltd.", "created": "February 23rd, 2021", "published": true, "pretty": null, "uri": "/contracts/628QitEAA73", "title": "September 24, 2020 Re: Amendment to Employment Agreement Dear Abi:", "group_id": "628QitEAA73", "group_samples": [{"label": "Employment Agreement (BioLineRx Ltd.)", "uri": "/contracts/628QitEAA73", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Amended and Restated License and Commercialization Agreement (the \u201cAgreement\u201d) is entered into this 26th day of August, 2009, by and among Ikaria Development Subsidiary One LLC, a Delaware limited liability company having a principal place of business at 6 State Route 173, Clinton, NJ 08809, USA (\u201cIkaria\u201d), BioLineRx Ltd., a corporation organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (\u201cBioLineRx Ltd.\u201d), and BioLine Innovations Jerusalem L.P., a limited partnership organized and existing under the laws of the State of Israel and having a principal place of business at 19 Hartum Street, P.O. Box 45158, Jerusalem 91450, Israel (\u201cBioLine Innovations\u201d; together with BioLineRx Ltd., \u201cBioLineRx\u201d).", "id": "642nEY2fakH", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891315000957/exhibit_4-17.htm", "category_name": "License and Commercialization Agreement", "company_name": "BioLineRx Ltd.", "created": "March 23rd, 2015", "published": true, "pretty": null, "uri": "/contracts/642nEY2fakH", "title": "LICENSE AND COMMERCIALIZATION AGREEMENT", "group_id": "642nEY2fakH", "group_samples": [{"label": "License and Commercialization Agreement (BioLineRx Ltd.)", "uri": "/contracts/642nEY2fakH", "published": true}], "group_size": 1, "tags": [{"name": "License and Commercialization Agreement", "type": "category", "uri": "/contracts/tagged/license-and-commercialization-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "AGREEMENT made as of the 9th day of January, 2007 by and between PAN ATLANTIC INVESTMENTS LIMITED, having an office at Musson Building, 2nd Floor, Hincks Street, Bridgetown BB11000, Barbados (\u201cPan Atlantic\u201d) and ROZEL INVESTMENTS LIMITED, having an office c/o Braun & Goldberg, 110 East 59th Street, Suite 3201, New York, New York 10022 (\u201cRozel\u201d) and CHAMPAGNE INVESTMENT HOLDINGS LTD, having an office at c/o Natalie Douglas Charles, Citco BVI Limited, Wickhams Cay 1, P.O. Box 662, Road Town, Tortola, British Virgin Islands (\u201cChampagne\u201d).", "id": "6KiZB9SrLB2", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000101905612000254/ex99_2.htm", "category_name": "Joint Venture Agreement", "company_name": "BioLineRx Ltd.", "created": "February 27th, 2012", "published": true, "pretty": null, "uri": "/contracts/6KiZB9SrLB2", "title": "JOINT VENTURE AGREEMENT", "group_id": "6KiZB9SrLB2", "group_samples": [{"label": "Joint Venture Agreement (BioLineRx Ltd.)", "uri": "/contracts/6KiZB9SrLB2", "published": true}], "group_size": 1, "tags": [{"name": "Joint Venture Agreement", "type": "category", "uri": "/contracts/tagged/joint-venture-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Registration Rights Agreement (the \u201cAgreement\u201d) made as of the __ day of January, 2007 by and among BioLine Rx Ltd., with a business address at 19 Hartum St., P.O. Box 45158, Jerusalem 91450, Israel (the \u201cCompany\u201d) and shareholders of the Company listed on Schedule 1 hereto (the \u201cHolders\u201d);", "id": "6XJeMXTp73u", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex3-1.htm", "category_name": "Registration Rights Agreement", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/6XJeMXTp73u", "title": "REGISTRATION RIGHTS AGREEMENT", "group_id": "6XJeMXTp73u", "group_samples": [{"label": "Registration Rights Agreement (BioLineRx Ltd.)", "uri": "/contracts/6XJeMXTp73u", "published": true}], "group_size": 1, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "TEL AVIV, Israel -- November 21, 2024\u2013 BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Ayrmid Ltd. (\u201cAyrmid\u201d), the parent company of Gamida Cell Ltd., today announced that on November 20, 2024, the companies entered into a license agreement for motixafortide (commercially sold in the U.S. as APHEXDA\u00ae), BioLineRx\u2019s FDA-approved stem cell mobilization agent indicated in combination with filgrastim (G-CSF) for collection and subsequent autologous transplantation in patients with multiple myeloma.", "id": "7dS1OjpV0Ja", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_99-1.htm", "category_name": "Exclusive License Agreement", "company_name": "BioLineRx Ltd.", "created": "November 21st, 2024", "published": true, "pretty": null, "uri": "/contracts/7dS1OjpV0Ja", "title": "BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA\u00ae (motixafortide) through Gamida Cell Ltd.", "group_id": "7dS1OjpV0Ja", "group_samples": [{"label": "Exclusive License Agreement (BioLineRx Ltd.)", "uri": "/contracts/7dS1OjpV0Ja", "published": true}], "group_size": 1, "tags": [{"name": "Exclusive License Agreement", "type": "category", "uri": "/contracts/tagged/exclusive-license-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Amendment No. 2 to the CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this \u201cAmendment No. 2\u201d), made as of the date of last signature hereunder (the \u201cAmendment No. 2 Effective Date\u201d), is by and between Merck Sharp & Dohme B.V. (\u201cMerck\u201d) and BioLineRx Ltd. (\u201cBioLineRx\u201d). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.", "id": "8fHhTxLi1tl", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891322001134/exhibit_4-20.htm", "category_name": "Clinical Trial Collaboration and Supply Agreement", "company_name": "BioLineRx Ltd.", "created": "March 16th, 2022", "published": true, "pretty": null, "uri": "/contracts/8fHhTxLi1tl", "title": "AMENDMENT NO. 2 TO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT", "group_id": "8fHhTxLi1tl", "group_samples": [{"label": "Clinical Trial Collaboration and Supply Agreement (BioLineRx Ltd.)", "uri": "/contracts/8fHhTxLi1tl", "published": true}], "group_size": 1, "tags": [{"name": "Clinical Trial Collaboration and Supply Agreement", "type": "category", "uri": "/contracts/tagged/clinical-trial-collaboration-and-supply-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Combination Study Agreement (\u201cAgreement\u201d) is made and entered into, effective as of September 6, 2016 (\u201cEffective Date\u201d), by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (\u201cGenentech\u201d) and BioLineRx Ltd., an Israeli company, having a principal place of business at Modi\u2019in Technology Park, 2 HaMa\u2019ayan Street, Modi\u2019in 7177871, Israel (\u201cBioLineRx\u201d). Genentech and BioLineRx are each referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "8vJJcCnFQiI", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891317000871/exhibit_4-42.htm", "category_name": "Combination Study Agreement", "company_name": "BioLineRx Ltd.", "created": "March 23rd, 2017", "published": true, "pretty": null, "uri": "/contracts/8vJJcCnFQiI", "title": "Combination Study Agreement", "group_id": "8vJJcCnFQiI", "group_samples": [{"label": "Combination Study Agreement (BioLineRx Ltd.)", "uri": "/contracts/8vJJcCnFQiI", "published": true}], "group_size": 1, "tags": [{"name": "Combination Study Agreement", "type": "category", "uri": "/contracts/tagged/combination-study-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Securities Purchase Agreement (this \u201cAgreement\u201d) is dated as of May 26, 2020, between BioLineRx Ltd., a company organized under the laws of Israel (the \u201cCompany\u201d), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a \u201cPurchaser\u201d and collectively the \u201cPurchasers\u201d).", "id": "9NvwIfogxTf", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000117891320001667/exhibit_10-1.htm", "category_name": "Securities Purchase Agreement", "company_name": "BioLineRx Ltd.", "created": "May 28th, 2020", "published": true, "pretty": null, "uri": "/contracts/9NvwIfogxTf", "title": "SECURITIES PURCHASE AGREEMENT", "group_id": "9NvwIfogxTf", "group_samples": [{"label": "Securities Purchase Agreement (BioLineRx Ltd.)", "uri": "/contracts/9NvwIfogxTf", "published": true}], "group_size": 1, "tags": [{"name": "Securities Purchase Agreement", "type": "category", "uri": "/contracts/tagged/securities-purchase-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "9pe9aylN4RT", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420410050815/v190859_ex10-20.htm", "category_name": "Unprotected Lease Agreement", "company_name": "BioLineRx Ltd.", "created": "September 24th, 2010", "published": true, "pretty": null, "uri": "/contracts/9pe9aylN4RT", "title": "Amendment and Update of the Unprotected Lease Agreement Between", "group_id": "9pe9aylN4RT", "group_samples": [{"label": "Unprotected Lease Agreement (BioLineRx Ltd.)", "uri": "/contracts/9pe9aylN4RT", "published": true}], "group_size": 1, "tags": [{"name": "Unprotected Lease Agreement", "type": "category", "uri": "/contracts/tagged/unprotected-lease-agreement"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}]}, {"intro": "Following the notice of termination of your employment, delivered to you by BioLineRx USA Inc. (\u201cthe Company\u201d) on January 13, 2011 in accordance with section 3.1 of your employment agreement dated as of January 2, 2008 (\u201cthe \u201cEmployment Agreement\u201d), this letter sets forth the terms and conditions that were mutually agreed upon between the Company and you regarding the termination, in addition to the termination terms provided in the Employment Agreement (the \u201cAdditional Terms\u201d).", "id": "aJk3onBV3Sj", "source_url": "https://www.sec.gov/Archives/edgar/data/1498403/000114420411038789/v227189_ex4-23.htm", "category_name": "Mutual Agreement Regarding Termination Terms", "company_name": "BioLineRx Ltd.", "created": "July 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/aJk3onBV3Sj", "title": "CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. BiolineRx Letterhead", "group_id": "aJk3onBV3Sj", "group_samples": [{"label": "Mutual Agreement Regarding Termination Terms (BioLineRx Ltd.)", "uri": "/contracts/aJk3onBV3Sj", "published": true}], "group_size": 1, "tags": [{"name": "Mutual Agreement Regarding Termination Terms", "type": "category", "uri": "/contracts/tagged/mutual-agreement-regarding-termination-terms"}, {"name": "BioLineRx Ltd.", "type": "company", "uri": "/company/1498403/biolinerx-ltd"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}], "next_curs": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLYUprM29uQlYzU2oYACAB", "cursor": "CjAKEAoKZ3JvdXBfc2l6ZRICCAIKGAoIZ3JvdXBfaWQSDBoKUXhyYU9OeWhCdxgAIAE="}}